MarketInOut Stock Screener Log In | Sign Up

Cullinan Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Cullinan Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization967.25 mln
Float48.50 mln
Earnings Date11/05/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

34.60
Transformational upside

Relative Strength

94 / 100
Top performer

Debt / Equity

0.01
Debt-free

ROE

-50.16
Deeply negative

ROA

-46.09
Deeply negative

Business Description

Cullinan Therapeutics is a Cambridge, Massachusetts-based drug development company focused on finding new treatments for cancer and autoimmune conditions. The company is currently running multiple clinical trials, testing several experimental medicines including targeted therapies for blood cancers, lung cancer, and autoimmune diseases. Cullinan works alongside a number of partners, including Taiho Pharmaceutical and Chongqing Genrix Biopharmaceutical, to bring its treatments to patients. Founded in 2016, the company operates under its current name following a rebranding in 2024.

Key Fundamentals

EPS-3.11
ROE-50.16
ROIC-191
ROA-46.09
EBITDA, mln-204
EV / EBITDA-2.83
EV / EBIT-2.83

Quote Details

Last 15.03
Change -0.42 (-2.72%)
Open 15.38
Volume 389,408
Turnover 5,852,802
Average Volume 772,054

Financial Ratios

Leverage Ratio1.13
Current Ratio8.42
Price / Book2.98
Price / Tangible Book2.97
Debt / Equity0.01

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price34.60
Short Ratio6.17
Short % of Float16.53

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.59% 84 / 100   
1 Month 3.44% 75 / 100   
2 Months -13.77% 37 / 100   
6 Months 11.91% 75 / 100   
1 Year 95.45% 91 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog